Q-omics provides the consensus-scored WHSC1L2P profile across patient tissues and cancer cell-line models. WHSC1L2P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WHSC1L2P is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, WHSC1L2P RNA expression shows 15,471 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where WHSC1L2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WHSC1L2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WHSC1L2P survival associations across molecular data types. WHSC1L2P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WHSC1L2P RNA expression–survival associations across cancer types. High WHSC1L2P expression shows unfavorable associations in KIRC, KIRP, LGG and LIHC, but favorable associations in CHOL and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for WHSC1L2P RNA expression.
This table summarizes WHSC1L2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for WHSC1L2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WHSC1L2P shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LUSC, LUAD and HNSC. The KICH box plot shows higher WHSC1L2P RNA expression in normal versus tumor tissue (log2 FC = −0.245, t-test p < 0.001).
This table shows molecular features associated with WHSC1L2P in patient tissues and cancer cell lines. In patient samples, WHSC1L2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
